Home Company News CHEMESIS: An Attractive Approach In The Growing Cannabis Market

CHEMESIS: An Attractive Approach In The Growing Cannabis Market

CHEMESIS:  An Attractive Approach In The Growing Cannabis Market


Since marijuana stocks hit the market, investors venturing into the sector have been able to reap serious profits, some over 1000% in a very short time span.  In fact, in 2017, Canopy Growth (WEED: TSX) and Aurora Cannabis (ACB: TSX) were among the list of Canada’s best-performing stocks. (Global News Money: June 30, 2018: Could Pot Stocks Make You Rich?)


So is it too late?  Did you miss the boat by not getting in on some of the more popular ones such as Canopy Growth or Aurora Cannabis at the beginning – and the latest stock craze, Tilray (TLRY: NASDAQ) which started trading on the Nasdaq in July, thereby becoming the first cannabis producer to complete an IPO on a U.S. stock exchange, at $17 USD which in 2 months sits around $100/share (as of September 24, 2018)? Probably not.


There are still companies venturing into this potentially very lucrative business with solid growth potential.  Chemesis International Inc. (CSI:CSE) (CADMF:NASDAQ), previously known as Canadian Mining Corp. is a company that is worth a look. I have been following it since it was a mining company and was trading at a fraction of what it is today. With its’ current stock price currently sitting around $1.53 CDN (as of September 24, 2018) and with recent aggressive expansion activity, it could present an attractive and affordable buy.  Keep in mind also that a stock that is at $1.50 can have a greater chance of higher percentage gains over the day than say, a stock that is listed at $60.  It does not take much to do the math that $1 gain on a $1.77 stock represents a 50% gain vs $1 gain on a $60 stock representing an approximately 1.6% gain. But it also works in reverse so be careful and do your due diligence.


The overall development plan presented by Chemesis makes it an interesting pick as far as the lower priced marijuana stocks go. A fully compliant seed-to-sale company, specializing in extraction techniques for the medical marijuana market, operations are currently based in Puerto Rico and California.  Since the legalization of the medical marijuana market in Puerto Rico in May 2017, Chemesis has been an innovative leader selling cannabis products in approximately seven locations across the state.


With regards to offerings, Chemesis is presenting potential clients numerous forms of extractions, formulations and products, with a specialization in BHO Extraction, Alchohol Extraction, and CO2 Extraction with a current capability production of 2,000 pounds a day.


Latest forecasts present an expected annual revenue of $6.7 million over the next 4 years with a net income of $2.8 million for the Puerto Rico market alone. (Investment News Network: 2018 Article: Bringing Vertically-Integrated Cannabis to Puerto Rico and California)


With the continual activities to grow the market stake in California, Chemesis ‘expected annual revenue in that state is projected to reach $61.5 million by year four with a net income of $27.2 million. The current medical marijuana market in California is estimated to be $3.7 billion in 2018 reaching $5.1 billion in 2019, leaving plenty of room for Chemesis to continue revenue growth.’  (Investment News Network: 2018 Article: Bringing Vertically-Integrated Cannabis to Puerto Rico and California)


In addition to developing their market reach in Puerto Rico and California, Chemesis intends to further expand operations globally within the realms of cultivation, manufacturing, distribution and retail sales.


Recent acquisitions as part of their planned growth include (as per their news releases):


Natural Ventures (Puerto Rico)

Chemesis holds an 80% stake in Puerto Rican based Natural Ventures, a manufacturer and distributor of cannabis products.  Natural Ventures is licensed to cultivate 100,000 sq. ft. of cannabis and currently holds a 35,000 sq. ft. manufacturing plant and has strategically aligned with major brands in the cannabis industry worldwide.  The acquisition is poised to position Chemesis as a leader in both medical and recreational cannabis cultivation and manufacturing.


SAP Global (Cathedral City, California)

SAP Global, a founding member of the National Cannabis Industry Association (NCIA) manufactures and distributes recreational cannabis products throughout California.  Currently, the company has the capacity to produce 2,000 pounds a day of raw material.  Chemesis has an 80% stake in the company.


California SAP (Cathedral City, California)

An award winning company focused on the California and Nevada markets, produces the highest quality CO2 extracts resulting in a high concentrate cannabis oil composed of 89% THC.  As of July 2018, Chemesis has an exclusive agreement allowing for the sale and distribution of 100 litres of high quality tested cannabis oil per month.  The agreement also allows Chemesis to increase its distribution and sales networks.



Desert Zen (Cathedral City, California)

Chemesis acquired 100% of Desert Zen in August 2018.  It is a licenced recreational and medicinal cannabis manufacturer, distributor and transport company.  The company has a tracking and monitoring system to ensure products meet all safety standards.  Desert Zen also has a large network of established farmers and dispensaries throughout California.


Desert Zen is actively seeking cultivators and manufacturers to join their sales, distribution and transportation network as well as distributors and dispensaries to feature their products in the Desert Zen catalogue.


In addition to the acquisitions, Chemesis recently closed $25 million CDN in equity financing with Alumina Partners, LLC. This will allow Chemesis to continue its growth strategy with financial support and funding available at their discretion.  Their strategy will allow for shareholder protection as Chemesis strategically grows to meet demands in California and globally.


With their current strategic ability to offer clients a large variety of extractions, formulations and products combined with an aggressive global development plan, Chemesis is one to watch as its’ reach continues on beyond the borders of California and Puerto Rico in both the medical marijuana market and the adult-use market presenting the very real potential to produce some serious gains for investors in the burgeoning and very lucrative cannabis market.

Happy Investing!


Dr. Kal Kotecha



© 2010 Junior Gold Report and TechMoney360

Junior Gold Report and TechMoney360 Newsletter: Junior Gold Report’s and Tech Money 360’s Newsletter is published as a copyright publication of Junior Gold Report (JGR) and TechMoney360 (TM360).  No Guarantee as to Content:  Although JGR/TM360 attempts to research thoroughly and present information based on sources we believe to be reliable, there are no guarantees as to the accuracy or completeness of the information contained herein. Any statements expressed are subject to change without notice. It may contain errors and you should not make any investment decisions based on what you have read on here. JGR/TM360, its associates, authors, and affiliates are not responsible for errors or omissions. By accessing the site and receiving this email, you accept and agree to be bound by and comply with the terms and conditions as set out herein. If you do not accept and agree to the terms you should not use the Junior Gold Report and TechMoney360 sites or accept this email. Consideration for Services: JGR/TM360, it’s editor, affiliates, associates, partners, family members, or contractors may have an interest or position in the featured companies (we have received 100,000 stock options of Chemesis), as well as sponsored companies which compensate JGR/TM360 as such our opinions are biased. We may hold potions in and trade these stocks of the companies we profile and as such our opinions are biased. JGR/TM360 and its’ owner and affiliates/associates may buy/sell and trade the featured companies from time to time. JGR/TM360 has been paid by the companies. Thus, multiple conflicts of interest exist. Therefore, information provided here within should not be construed as a financial analysis but rather as an advertisement. Conduct your own due diligence: The author’s views and opinions regarding the companies featured in report(s) are his/her own views and are based on information that he/she has researched independently and has received, which the author assumes to be reliable. You should never base any buying/selling/trading decisions off of our emails, newsletter, website, videos or any of our published materials. JGR/TM360 aims to provide information and often stock ideas but are by no means recommendations. The ideas and companies featured are highly speculative and you could lose your entire investment – consult a licensed financial advisor if you are considering investing in any of the featured companies. Subscribers/readers are encouraged to conduct their own research and due diligence. The companies mentioned are high risk and considered penny stocks that contain a high risk of volatility, therefore consult your investment advisor and do your own due diligence before purchasing. Never base any investment decision on information contained from our emails, newsletter, website, videos or any of our published materials. No Offer to Sell Securities: JGR/TM360 is not a registered broker dealer, investment advisor, financial analyst, stock picker, investment banker or other investment professional. JGR/TM360 is intended for informational, educational and research purposes only. It is not to be considered as investment advice. No statement or expression of any opinions contained in this report constitutes an offer to buy or sell the shares of the companies mentioned herein. Links: JGR/TM360 may contain links to related websites for stock quotes, charts, etc. JGR/TM360 is not responsible for the content of or the privacy practices of these sites. Information contained herein was extracted from public filings, profiled company websites, and other publicly available sources deemed reliable. Information in this report was taken on or before writing and dissemination and may not be updated. Do you own due diligence as information and events can and do change. Published reports may reference company websites or link to company websites and we disclaim and responsibility for the content and accuracy of any such information or website. Release of Liability: By reading and/or watching videos by JGR/TM360, you agree to hold JGR/TM360, its associates, sponsors, affiliates, and partners harmless and to completely release them from any and all liabilities due to any and all losses, damages, or injuries (financial or otherwise) that may be incurred.


Forward Looking Statements
Except for statements of historical fact, certain information contained herein constitutes forward-looking statements. Forward looking statements are usually identified by the use of certain terminology, including “will”, “believes”, “may”, “expects”, “should”, “seeks”, “anticipates”, “has potential to”, or “intends’ or by discussions of strategy, forward looking numbers or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results or achievements to be materially different from any future results or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts, and include but are not limited to, estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to the effectiveness of the Company’s business model; future operations, products and services; the impact of regulatory initiatives on the Company’s operations; the size of and opportunities related to the market for the Company’s products; general industry and macroeconomic growth rates; expectations related to possible joint and/or strategic ventures and statements regarding future performance. Junior Gold Report/TechMoney360 does not take responsibility for the accuracy of forward looking statements and advises the reader to perform their own due diligence on forward looking numbers or statements.